

# R H I N O M E D

## Chairman's Address to Shareholders – 2014 AGM

---

**29 October 2014**  
**Melbourne, Australia.**

Welcome to the fiscal year 2013-2014 Annual General Meeting for Rhinomed Ltd. I am Martin Rogers, your Chairman.

It gives me great pleasure to be standing here today at the home of Sport in Melbourne – the MCG, talking about the significant turnaround that your company has undergone in the last financial year. This is indeed the site of some great come backs in the sporting arena and so too is Rhinomed a great story of a comeback.

With a renewed focus and a solid strategy to develop products in the respiratory and breathing management space, I am proud to not only see but also hear from shareholders and the investment community at large, that we have turned the corner and now on a clear path of rebuilding shareholder value.

The past year has been one of considerable growth and progress as we continued to develop nasal, respiratory and respiratory technologies for the treatment of obstructive sleep apnea (OSA) and other breathing and nasal disorders.

One major change of note is the Company's name. In November 2013 we formally advised of a change in the Company's name to Rhinomed Limited (under the ASX code RNO), replacing the Company's previous name, Consegna Limited. The name change better represents the specific area of medicine, and markets, that the Company is pursuing.

Our goal is to commercialise our BreatheAssist technology in the Sport, Sleep, Wellbeing and Drug Delivery markets globally, and I am pleased to report that significant progress has been achieved toward this goal. In January 2014, we launched our first product, Turbine™ in to the global sports and exercise market, at the Tour Down Under professional cycling race in South Australia. Turbine™ is designed to deliver increased airflow through nasal passages, for both professional and amateur athletes alike.

Following this an independent high performance product trial was carried out by former Olympic Cyclist Rob Crowe at Ridewiser Studio in Melbourne, Australia and was announced on 13th May 2014. The results were exciting and compelling, with two-thirds of professional high performance riders increasing their power output in the trial at average of 6.5%.

We have been delighted with the uptake of Turbine™, and in July 2014 it was formally registered by the US Food and Drug Administration. By utilising sport and exercise as a market entry strategy, Rhinomed has been able to successfully engage and inform people about the importance of their breathing during exercise, and this has provided an excellent leverage point into the Company's broader product range.

# R H I N O M E D

Rhinomed plans to launch its BreatheAssist-based products in to the Sleep market by the end of calendar year 2014, and then in the Wellbeing and Drug Delivery markets, progressively, in 2015.

In the Drug Delivery market, we are seeking to develop our technology as a viable delivery mechanism for the Sumatriptan drug in the treatment of migraine headaches. This in itself represents a massive global market opportunity valued at around \$1.6 billion. Also during the year, the Company strengthened its board and management to best position it for the commercialisation and roll-out of its product range.

Former Nike Inc. Vice President and Chief Executive of Western Europe, Mr Brent Scrimshaw, and University of Sydney Business School senior lecturer, Dr Eric Knight, joined the board as Non-executive Directors. Also, Lord Simon Reading stepped down from the board, and on behalf of the Company, we thank him for his contribution to Rhinomed and wish him well in his future endeavours.

Financially, your Company remains well funded to pursue its goals and objectives, and it will continue to adhere to a prudent and considered approach to capital management. Finally, as Chairman of the Board I know I can speak for my fellow Directors in assuring investors that we remain committed to developing a business that in time grows in value and continues to extract full value from the assets under our management. The entire Rhinomed team remains focused on delivering new products to assist peoples' nasal, respiratory and respiratory issues, and I look forward to sharing news of our progress with you in the year ahead and thank you for your attendance.

## Media Enquiries

Michael Johnson, CEO & Director  
+61 (03) 8416 0900  
[mjohnson@rhinomed.com.au](mailto:mjohnson@rhinomed.com.au)

Follow us on twitter  @rhinomedceo and @theturbinecom

## About Rhinomed Limited (ASX:RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise application of its BreatheAssist technology portfolio in the Sport, Snoring, Olfactory, Sleep and Drug Delivery markets. It is launching its first Product the Turbine™ nasal dilator later this year. For more information go to <http://www.rhinomed.com.au>.

## About the Turbine™

The Turbine™ is a revolutionary product, which utilises the BreatheAssist technology and can deliver to athletes on average 38% increase in airflow through the nasal passages. The Turbine™ product range has been designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training.